Status:
COMPLETED
PROstate Cancer Imaging, Treatment and Toxicity (PROCITT)
Lead Sponsor:
Calvary Mater Newcastle, Australia
Collaborating Sponsors:
Abbott
Conditions:
Prostate Cancer
Eligibility:
MALE
Brief Summary
This is a single centre prospective observational noninterventional study of men with histological confirmed prostate cancer, high risk disease and not positive for metastatic disease planned to recei...
Detailed Description
1. ADT induced Osteoporosis Prostate cancer is a common malignancy in Australian men. In men with localized disease at the time of diagnosis, baseline PSA level, tumour stage and Gleason grade can...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Patient capable of giving informed consent
- Histological diagnosis of prostate cancer
- High risk disease defined by any one of:
- Baseline PSA\>20
- Gleason grade 8 disease
- Clinical stage T3-T4
- Negative conventional staging in the form of a:
- T99m whole body bone scan
- CT of the abdomen and pelvis
- No previous pelvic radiotherapy
- Exclusion Criteria
- History of prior malignancy within the last 5 years with the exception of non-melanomatous skin cancers.
- ECOG performance status \>1
- Inability to have intraprostatic fiducials inserted.
- Inability to be given an MRI due to:
- Implanted magnetic metal eg intraocular metal
- Pacemaker / Implantable defibrillator
- Extreme claustrophobia
Exclusion
Key Trial Info
Start Date :
November 28 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 20 2017
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT01418040
Start Date
November 28 2012
End Date
July 20 2017
Last Update
February 5 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Calvary Mater Newcastle
Waratah, New South Wales, Australia, 2305